Age: 19.0
Sex: F
Vaccine: COVID19-2
Symptoms: Inappropriate schedule of product administration, No adverse event
Clinical narrative: No adverse event; accidentally administered 1 dose of Moderna COVID-19 Vaccine Bivalent on 24MAY2023 before minimum interval, 5 weeks after patient received 1st dose of primary series (monovalent) on 18APR2023; This spontaneous case was reported by a nurse and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (accidentally administered 1 dose of Moderna COVID-19 Vaccine Bivalent on 24MAY2023 before minimum interval, 5 weeks after patient received 1st dose of primary series (monovalent) on 18APR2023) and NO ADVERSE EVENT (No adverse event) in a 19-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7170B) for COVID-19 prophylaxis.     The patient had no known conditions.     On 24-May-2023, the patient received second dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .5 milliliter. On 24-May-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (accidentally administered 1 dose of Moderna COVID-19 Vaccine Bivalent on 24MAY2023 before minimum interval, 5 weeks after patient received 1st dose of primary series (monovalent) on 18APR2023). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (accidentally administered 1 dose of Moderna COVID-19 Vaccine Bivalent on 24MAY2023 before minimum interval, 5 weeks after patient received 1st dose of primary series (monovalent) on 18APR2023) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (accidentally administered 1 dose of Moderna COVID-19 Vaccine Bivalent on 24MAY2023 before minimum interval, 5 weeks after patient received 1st dose of primary series (monovalent) on 18APR2023).    No concomitant medications were reported.  The patient received first dose of the primary series (monovalent) on 18-Apr-2023. Patient was instructed to come back in four weeks to receive her second dose of monovalent to complete the series. The patient came as instructed however the monovalent was no longer authorized to use and was given bivalent dose to complete her immunization.   Reporter later realized that the bivalent dose was given too soon.  Patient was instructed to come back in 2 month to receive another bivalent dose for validation.  No adverse events were reported.  No treatment medications were reported.   This case was linked to MOD-2023-726268 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 16-Jun-2023: Follow-up received include reporter details updated, patient details (Race and ethnicity) updated, Suspect product dose details updated, iNarrative updated